Advertisement
Screener

Zoetis Inc. (ZTS) Debt / Equity

Zoetis Inc. Debt/Equity Ratio

The debt/equity ratio shows how much a company has borrowed for every dollar its shareholders have put in. It is long-term debt, both the part due within a year and the rest, divided by shareholder equity, shown as a multiple with both amounts in the table. A higher ratio means the company relies more on borrowed money than on shareholder capital. Because equity shrinks through buybacks or losses, the ratio can rise even when debt is unchanged, and it has no meaning when equity is negative. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

  • Zoetis Inc. debt/equity ratio for the quarter ending 2025-12-31 was 2.65, a 95.21% increase year-over-year.
  • Zoetis Inc. debt/equity ratio for the quarter ending 2025-09-30 was 1.31.
  • Zoetis Inc. debt/equity ratio for the quarter ending 2025-06-30 was 1.28.
  • Zoetis Inc. debt/equity ratio for the quarter ending 2025-03-31 was 1.35.
  • Zoetis Inc. debt/equity ratio for fiscal 2025 was 2.71, a 97.08% increase from fiscal 2024.
  • Zoetis Inc. debt/equity ratio for fiscal 2024 was 1.38, a 4.73% increase from fiscal 2023.
  • Zoetis Inc. debt/equity ratio for fiscal 2023 was 1.32, a 26.72% decline from fiscal 2022.
  • Zoetis Inc. debt/equity ratio for fiscal 2022 was 1.79, a 23.71% increase from fiscal 2021.
Available history
2014-12-31 to 2025-12-31
Data captured

Historical Debt/Equity Ratio

DateDebt/Equity RatioLong-term debtShareholder equity
2025-12-312.65$9.04B$3.42B
2025-09-301.31$7.07B$5.4B
2025-06-301.28$6.58B$5.16B
2025-03-311.35$6.58B$4.87B
2024-12-311.36$6.57B$4.84B
2023-12-311.32$6.56B$4.99B
2023-09-301.29$6.55B$5.07B
2023-06-301.42$6.56B$4.62B
2023-03-311.46$6.56B$4.49B
2022-12-311.79$7.9B$4.4B
2022-09-301.41$6.56B$4.66B
2022-06-301.43$6.57B$4.58B
2022-03-311.41$6.58B$4.66B
2021-12-311.45$6.59B$4.54B
2021-09-301.41$6.59B$4.68B
2021-06-301.65$7.19B$4.35B
2021-03-311.76$7.19B$4.09B
2020-12-311.91$7.2B$3.77B
2020-09-302.13$7.7B$3.61B
2020-06-302.58$7.69B$2.99B
2020-03-312.35$6.46B$2.75B
2019-12-312.38$6.45B$2.71B
2018-12-312.95$6.44B$2.19B
2017-12-312.77$4.95B$1.79B
2017-10-012.82$5.7B$2.02B
2017-07-022.56$4.47B$1.75B
2017-04-022.73$4.47B$1.64B
2016-12-312.98$4.47B$1.5B
2016-10-022.8$4.47B$1.6B
2016-07-033.26$4.47B$1.37B
2016-04-033.76$4.46B$1.19B
2015-12-314.46$4.86B$1.09B
2015-09-272.89$3.63B$1.25B
2015-06-283.03$3.64B$1.2B
2015-03-292.79$3.64B$1.31B
2014-12-312.71$3.62B$1.34B

Annual Debt/Equity Ratio

DateDebt/Equity RatioLong-term debtShareholder equity
2025-12-312.71$9.04B$3.33B
2024-12-311.38$6.57B$4.77B
2023-12-311.32$6.56B$4.99B
2022-12-311.79$7.9B$4.4B
2021-12-311.45$6.59B$4.54B
2020-12-311.91$7.2B$3.77B
2019-12-312.38$6.45B$2.71B
2018-12-312.95$6.44B$2.19B
2017-12-312.77$4.95B$1.79B
2016-12-312.98$4.47B$1.5B
2015-12-314.46$4.86B$1.09B
2014-12-312.71$3.62B$1.34B

Similar stocks

Stock NameCountryMarket CapPE Ratio
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10